RT @doctorRBC: Sarilumab in pts with relapsing PMR - Phase 3 trial Sarilumab +14 week steroid taper - higher sustained R
Tweet Content
Sarilumab in pts with relapsing PMR - Phase 3 trial
Sarilumab +14 week steroid taper - higher sustained Remission than w/o sarilumab (28% vs 10%)
Less flare occurrences
Sarilumab noted to have higher incidences of neutropenia, arthralgia
@RheumNow #EULAR2022 ABST#LB0006 https://t.co/SeetkBsYI3
Show on Archive Page
On
Display in Search Results
On
PDQ
Off